Multiplex STI PCR Testing: Detecting 10 Sexually Transmitted Pathogens in One Test

sti pcr test

Sexually transmitted infections do not always present clearly. A patient may have discharge, genital discomfort, an ulcer or lower abdominal pain.

Another patient may have no symptoms at all.

And even where symptoms are present, several sexually transmitted pathogens can produce similar clinical presentations.

This creates a familiar problem for clinicians and laboratories:

  • Which pathogen should we test for first?

The question becomes even more important when co-infections are possible.

A patient may not necessarily have one sexually transmitted infection. More than one pathogen may be present at the same time, meaning a narrowly targeted testing strategy can potentially miss clinically relevant information.

The Bosch Vivalytic STI test addresses this problem by simultaneously testing for 10 sexually transmitted pathogens from a single patient sample. Bosch describes it as a fully automated, DNA-based molecular test using genital swabs and/or urine specimens.

Why Is STI Testing Particularly Relevant in Africa?

sti testing

The African Region carries a substantial burden of sexually transmitted infections.

WHO’s Regional Office for Africa has historically described STIs as highly endemic across the region. Earlier regional estimates suggested that Africa accounted for a disproportionately large share of global curable STI incidence.

WHO Africa has also highlighted the scale of the problem in public-health campaigns, noting the significant burden of curable STIs, syphilis, genital herpes and related sexual-health conditions across the continent.

However, one of the challenges has been limited and uneven surveillance data.

WHO has acknowledged that reliable prevalence information can be sparse in some African settings, making it difficult to accurately estimate disease burden or determine which pathogens predominate within particular populations.

  • This makes laboratory capacity especially important.
  • And Better testing produces better patient information.

Over time, appropriately aggregated diagnostic data can also improve understanding of which infections are actually circulating within a population.

Why Can Testing One Pathogen at a Time Be Limiting?

Consider a patient presenting with genital discharge.

Several organisms may plausibly be responsible.

If the laboratory initially tests only for Chlamydia trachomatis and the result is negative, another assay may then be ordered.

If that result is negative, further testing may follow.

This sequential approach can sometimes be clinically appropriate.

But it can also create:

  • additional laboratory steps;
  • additional patient sampling;
  • delayed diagnosis;
  • repeat visits;
  • and the possibility that co-infections are overlooked.

Multiplex molecular testing approaches the problem differently.

Instead of asking: “Which single pathogen should we investigate first?”

the assay asks: “Which of these clinically relevant pathogens are present in this sample?”

That is the central advantage of multiplex STI diagnostics.

What Does the Vivalytic STI Test Detect?

What Does the Vivalytic STI Test Detect?

The Vivalytic STI assay detects 10 sexually transmitted pathogens in a single test.

According to Bosch, these include:

PathogenType
Chlamydia trachomatisBacterium
Neisseria gonorrhoeaeBacterium
Trichomonas vaginalisParasite
Treponema pallidumBacterium
Herpes simplex virus 1Virus
Herpes simplex virus 2Virus
Mycoplasma genitaliumBacterium
Mycoplasma hominisBacterium
Ureaplasma urealyticumBacterium
Haemophilus ducreyiBacterium

Bosch describes this as two viruses, seven bacteria and one parasite detected within the same assay.

This means the test covers organisms associated with several different STI syndromes, including:

  • urethritis,
  • cervicitis,
  • genital ulcer disease and
  • other reproductive or sexual-health presentations.

1. Why Is Chlamydia Important?

Chlamydia trachomatis is one of the most common curable sexually transmitted infections worldwide.

It frequently causes no symptoms.

When untreated, however, infection can contribute to complications including pelvic inflammatory disease, infertility and ectopic pregnancy. WHO specifically identifies chlamydia and gonorrhoea as important causes of pelvic inflammatory disease and infertility.

This makes chlamydia a good example of why symptom-based diagnosis can be insufficient.

A patient may feel perfectly well and still have an infection capable of causing longer-term reproductive-health consequences.

2. Why Is Gonorrhoea Especially Important?

In addition to its clinical effects, gonorrhoea has become increasingly important because of antimicrobial resistance.

  • WHO identifies rapidly increasing drug resistance in gonorrhoea as a major threat to STI control.

Detecting N. gonorrhoeae tells clinicians that the organism is present, it does not necessarily provide complete antimicrobial susceptibility information.

Culture and antimicrobial susceptibility testing may therefore continue to have important roles, particularly for surveillance, treatment failure and resistance monitoring.

PCR should be considered one component of an appropriate diagnostic strategy rather than a replacement for every microbiological technique.

3. Why Include Trichomonas Vaginalis?

Trichomonas vaginalis is a parasitic sexually transmitted infection.

WHO includes trichomoniasis among the four major curable STIs responsible for hundreds of millions of new infections globally.

Like several other STIs, trichomoniasis may occur without obvious symptoms.

Including T. vaginalis within a multiplex assay therefore broadens the diagnostic scope beyond bacterial and viral infections.

This is useful because the clinical syndrome alone may not make the causative organism obvious.

4. Herpes Simplex Virus 1 and 2.

Herpes simplex virus can cause genital herpes.

HSV-2 is particularly associated with genital infection, although HSV-1 can also cause genital disease.

WHO estimates that approximately 520 million people aged 15–49 globally have HSV-2 infection.

Genital ulcers can have several infectious causes.

Including both HSV-1 and HSV-2 alongside organisms such as Treponema pallidum and Haemophilus ducreyi means the assay can investigate several potential pathogens associated with genital ulcer presentations.

5. Why Are Mycoplasma and Ureaplasma Included?

The Vivalytic STI test also detects:

  • Mycoplasma genitalium
  • Mycoplasma hominis and
  • Ureaplasma urealyticum.

These organisms require particularly careful clinical interpretation.

M. genitalium is recognised as an STI-associated pathogen and can contribute to urethritis and reproductive-tract disease.

However, organisms such as M. hominis and Ureaplasma species can also be found in people without symptoms, meaning detection alone does not always establish that they are responsible for a patient’s illness.

Bosch itself distinguishes its broader 10-pathogen STI assay from the more targeted Vivalytic MG, MH, UP/UU test, which detects M. genitalium, M. hominis and Ureaplasma parvum/urealyticum in a separate approximately one-hour real-time PCR assay.

This is another reminder that molecular detection and clinical diagnosis are related, but they are not identical.

6. What About Syphilis?

The Vivalytic panel includes Treponema pallidum, the bacterium that causes syphilis.

Syphilis is particularly important because untreated infection can cause serious complications and can also be transmitted during pregnancy.

WHO estimated that approximately 1.1 million pregnant women had syphilis in 2022, contributing to more than 390,000 adverse birth outcomes worldwide.

However, syphilis diagnosis is complex.

Molecular detection from appropriate specimens may provide useful information in specific circumstances, but serological testing remains central to routine syphilis diagnosis and screening.

Healthcare organisations should therefore integrate PCR results into appropriate diagnostic algorithms rather than treating a multiplex molecular assay as a universal replacement for established syphilis testing pathways.


How Does the Vivalytic STI Test Work?

sti vivalytic mg, mh, up/uu

Bosch describes Vivalytic STI as a DNA-based multiplex molecular assay.

It accepts:

  • urine samples and
  • urogenital swabs, which include vaginal, cervical and urethral specimens according to the Vivalytic portfolio information.

The test runs fully automatically within the Vivalytic analyser.

The product portfolio supplied for MediDiagAfrica specifies a testing time of approximately 2 hours 20 minutes, with a sample volume of 300 μL per test.

SpecificationVivalytic STI
Number of Pathogens10
Detection TechnologyPCR-based microarray
Sample MaterialUrine, preferably first void;
urogenital swabs such as vaginal, cervical or urethral
Time-to-ResultApprox. 2 hours 20 minutes
Intended SettingProfessional and laboratory use;
Near Patient Testing
Sample Volume300 μL per test
Transport Medium1 ml eNAT® (Copan)
Compatible SwabsFLOQSwabs® Regular sterile and MiniTip sterile

Bosch’s current public material similarly describes the assay as capable of analysing one patient sample for ten pathogens simultaneously and operating through a fully automated workflow.

Healthcare professionals can review the official Bosch Vivalytic STI test information.

Could One Sample Reduce Repeat Testing?

Potentially.

A broad STI panel may reduce the need to perform several independent molecular assays when multiple pathogens are clinically relevant.

That can be useful where obtaining another sample would otherwise require:

  • a second patient visit;
  • repeat specimen collection;
  • additional laboratory handling;
  • or referral to another facility.

But multiplex testing is not automatically the most economical strategy for every patient.

If there is one very specific diagnostic question, a targeted assay may be more appropriate.

The value of multiplexing increases when several pathogens are reasonably plausible or when co-infections are an important concern.

Why STI Diagnostics Can Be Particularly Valuable at the Point of Care

STI management faces a practical problem that is sometimes underestimated:

patients do not always return.

Where testing involves sending specimens to another laboratory and asking the patient to return several days later, loss to follow-up can complicate diagnosis and treatment.

  • Faster molecular diagnostics may potentially shorten that pathway.

Bosch positions Vivalytic as suitable for clinics, practices and laboratories and highlights the value of fully automated testing closer to the point of care.

This does not mean the 10-pathogen assay creates an immediate result, in fact, the test takes approximately 2 hours 20 minutes according to the supplied portfolio.

But in some healthcare settings, same-day or near-patient testing may still represent a substantial improvement over external referral and delayed reporting.

Does Multiplex PCR Replace Every Conventional STI Test?

No.

This is an important limitation to state clearly.

Different sexually transmitted infections require different diagnostic strategies.

Some organisms may require:

  • serology;
  • culture;
  • microscopy;
  • antimicrobial susceptibility testing;
  • additional molecular testing;
  • or clinical examination.

Gonorrhoea is a particularly important example because antimicrobial susceptibility information remains crucial as resistance continues to develop.

Syphilis also has established serological diagnostic pathways that remain essential.

A multiplex PCR panel should therefore be seen as one powerful molecular diagnostic tool within a broader STI service, not a replacement for every laboratory method.

Why This Matters for African Laboratories

african laboratory

The African STI burden is considerable, but diagnostic capacity is uneven.

Expanding access to molecular diagnostics could therefore help selected hospitals, sexual-health services and laboratories move toward more etiological diagnosis – or identifying the organism actually present.

But that does not mean every clinic needs a molecular analyser.

The appropriate level of diagnostic investment depends on:

  • patient volumes;
  • clinical services;
  • available infrastructure;
  • local disease patterns;
  • staff capacity;
  • test costs;
  • and referral networks.

The Vivalytic STI Portfolio Is Broader Than One Multiplex Test

vivalytic mpxv

Bosch currently groups three applications within its sexually transmitted infection portfolio:

  • Vivalytic STI: the broad 10-pathogen multiplex assay;
  • Vivalytic MG, MH, UP/UU: an approximately one-hour real-time PCR test targeting Mycoplasma genitalium, M. hominis and Ureaplasma parvum/urealyticum;
  • Vivalytic MPXV: which Bosch currently labels ‘Research Use Only and not for diagnostic procedures.’

This provides flexibility.

A laboratory may not need to perform the broad 10-pathogen panel for every patient.

Depending on the clinical question, a more focused molecular assay may be appropriate.

Questions Laboratory Managers Should Consider

Before introducing multiplex STI PCR testing, healthcare organisations should consider:

  • Which STI pathogens do we currently test for?
  • How many samples do we process each month?
  • Which tests are performed locally and which are referred externally?
  • What is our current sample-to-result turnaround time?
  • How frequently do clinicians request testing for multiple pathogens?
  • How commonly are patients lost to follow-up before results become available?
  • Would broader testing help identify clinically relevant co-infections?
  • Which positive results require confirmation or additional testing?
  • How would gonorrhoea antimicrobial susceptibility testing be handled?
  • Which syphilis diagnostic tests would remain part of the laboratory algorithm?
  • What specimen types do we currently collect?
  • What molecular infrastructure do we already have?
  • How reliably can cartridges and consumables be supplied?
  • What technical, training and after-sales support is available?
  • Could the same Vivalytic platform support molecular testing outside the STI service?

These questions help determine whether multiplex testing addresses a genuine healthcare need rather than simply increasing the number of detectable organisms.

Is Your Organisation Considering Multiplex STI PCR Testing?

If your clinic, hospital, diagnostic laboratory or reproductive-health service is reviewing its STI testing or wider molecular diagnostic capabilities, MediDiagAfrica can provide further information about the Bosch Vivalytic platform and Vivalytic STI assay.

The discussion can begin with your current pathway:

  • Which STIs do you currently test for?
  • Are samples processed within your organisation or referred elsewhere?
  • How quickly do patients receive results?
  • How often do you need to investigate several pathogens or possible co-infections?
  • Would a broad multiplex assay or a more targeted STI PCR approach better fit your service?

From there, you can:

Request information about the Vivalytic STI test

Request a Vivalytic demonstration

Enquire about Vivalytic availability in your country

Bosch advises that individual Vivalytic products may not be available in every region, so availability should be confirmed for the relevant market before procurement.

This article is intended for healthcare and laboratory professionals and provides general diagnostic and product information. It should not replace clinical guidelines, professional medical judgement, local STI diagnostic algorithms, antimicrobial susceptibility testing or applicable regulatory requirements.


Leave a Reply